Aivocode, Inc.
San Diego, CA
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Physical address
- 9276 Scranton Rd #500, San Diego, CA 92121, USA
- Website
- aivocode.com
- Employees
- 1-10
- Estimated annual revenue
- $0-$1M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Biotechnology
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract subawards
| Prime contractor | Prime award | Amount | Awarded |
|---|---|---|---|
| Battelle Memorial Institute | HR001124C0370 | $670,057 |
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Research And Development | San Diego, CA | — |
| Neurodex Inc. | Natick, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Artery Therapeutics, Inc. | San Ramon, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Bolden Therapeutics Inc. | Providence, RI | — |
| Formation Venture Engineering Foundry Inc. | Topsfield, MA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
Aivocode, Inc. is a biotechnology company located in San Diego, California, specializing in advanced therapeutic research and development focusing on neurodegenerative diseases and brain injury treatments. Registered in SAM.gov since 2015, the company is a for-profit corporate entity that develops innovative therapeutic approaches, particularly targeting Alzheimer's disease and traumatic brain injury. The company appears to concentrate on developing novel peptide and antibody-based treatments, leveraging advanced biotechnology techniques such as in vivo phage display and targeted molecular approaches to address complex neurological conditions.
Regarding federal contract work, Aivocode, Inc. has demonstrated involvement in federal contract activities through a sub-contract award with Battelle Memorial Institute dated April 17, 2024. The specific sub-contract involves synthesizing and characterizing peptides as potential countermeasures, indicating the company's capabilities in advanced peptide research and development for potentially defense or medical applications. While the available information suggests limited direct prime federal contract awards, the company has established collaborative relationships with prominent research institutions and federal research agencies through its sub-contract work.
In terms of federal grant awards, Aivocode, Inc. has secured significant funding from federal agencies, particularly the National Institute on Aging (NIA) and the National Institute of Neurological Disorders and Stroke. The company has received multiple grants focusing on innovative therapeutic approaches for Alzheimer's disease and traumatic brain injury. Specific grant projects include developing single domain antibodies to target Connective Tissue Growth Factor (CTGF) for improving vascular dysfunction in Alzheimer's disease, a $1,244,775 award running from September 2025 to May 2027, and a project developing CAQK, a proprietary peptide for managing traumatic brain injury, with a grant aimed at completing preclinical development activities for potential FDA investigational new drug application. These grants demonstrate Aivocode's commitment to advancing neurological disease treatments through sophisticated molecular research strategies.
SBA capabilities narrative
Development of probes for detection of different diseases
Quick answers
Is Aivocode, Inc. registered in SAM.gov?
Yes. Aivocode, Inc.'s SAM.gov registration is active through July 2, 2027.
What is Aivocode, Inc.'s CAGE code?
Aivocode, Inc.'s CAGE code is 7BT98, and its Unique Entity ID (UEI) is TLPZZJEMNND1.
What is Aivocode, Inc.'s most recent federal award?
Aivocode, Inc.'s most recent federal grant award is Single domain antibody development for improving vascular dysfunction in alzheimer's disease - alzheimer's disease (ad)… (R44AG097127), from National Institute on Aging (NIH), on September 20, 2025.
On GovTribe
See Aivocode, Inc.'s full federal record
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors